| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 49 | 2011 | 156 | 4.980 |
Why?
|
| Neurons | 31 | 2011 | 374 | 3.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 13 | 2009 | 24 | 2.360 |
Why?
|
| Corpus Striatum | 23 | 2014 | 111 | 2.260 |
Why?
|
| Mesencephalon | 14 | 2001 | 44 | 1.650 |
Why?
|
| Rats | 52 | 2014 | 854 | 1.570 |
Why?
|
| Animals | 79 | 2014 | 4552 | 1.360 |
Why?
|
| Lipopolysaccharides | 8 | 2009 | 127 | 1.300 |
Why?
|
| Parkinson Disease | 26 | 2013 | 1164 | 1.290 |
Why?
|
| Nerve Growth Factors | 11 | 2005 | 44 | 1.190 |
Why?
|
| Rats, Sprague-Dawley | 29 | 2014 | 451 | 1.170 |
Why?
|
| Substantia Nigra | 13 | 2014 | 148 | 1.150 |
Why?
|
| Cocaine | 8 | 2002 | 46 | 1.110 |
Why?
|
| Blood-Brain Barrier | 7 | 2009 | 43 | 1.080 |
Why?
|
| Nerve Degeneration | 7 | 2009 | 55 | 1.080 |
Why?
|
| Levodopa | 16 | 2002 | 142 | 0.850 |
Why?
|
| Parkinson Disease, Secondary | 5 | 2014 | 29 | 0.810 |
Why?
|
| Tyrosine 3-Monooxygenase | 18 | 2013 | 83 | 0.810 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2007 | 215 | 0.750 |
Why?
|
| Brain | 17 | 2014 | 1689 | 0.730 |
Why?
|
| Pregnancy | 19 | 2009 | 403 | 0.720 |
Why?
|
| Thiazoles | 5 | 2002 | 35 | 0.720 |
Why?
|
| Methamphetamine | 3 | 2014 | 48 | 0.700 |
Why?
|
| Hypoxia, Brain | 4 | 2011 | 14 | 0.690 |
Why?
|
| Haloperidol | 16 | 1992 | 31 | 0.680 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2014 | 18 | 0.680 |
Why?
|
| Dopamine Agonists | 4 | 2000 | 46 | 0.650 |
Why?
|
| Myoclonus | 10 | 2001 | 29 | 0.630 |
Why?
|
| Nerve Tissue Proteins | 9 | 2004 | 173 | 0.620 |
Why?
|
| Cell Count | 10 | 2009 | 99 | 0.590 |
Why?
|
| Hypoxia | 5 | 2014 | 60 | 0.580 |
Why?
|
| Disease Models, Animal | 16 | 2013 | 724 | 0.580 |
Why?
|
| Antiparkinson Agents | 6 | 2002 | 130 | 0.540 |
Why?
|
| Microvessels | 1 | 2014 | 16 | 0.500 |
Why?
|
| Oxidopamine | 7 | 2006 | 24 | 0.480 |
Why?
|
| Cells, Cultured | 18 | 2001 | 676 | 0.460 |
Why?
|
| Neostriatum | 6 | 2007 | 22 | 0.460 |
Why?
|
| Stem Cells | 3 | 1999 | 46 | 0.460 |
Why?
|
| Stereotyped Behavior | 16 | 1990 | 30 | 0.450 |
Why?
|
| Male | 46 | 2014 | 15621 | 0.440 |
Why?
|
| Carbidopa | 10 | 2002 | 45 | 0.420 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2011 | 10 | 0.420 |
Why?
|
| Aging | 8 | 2008 | 1593 | 0.410 |
Why?
|
| Cell Death | 6 | 2007 | 61 | 0.410 |
Why?
|
| MPTP Poisoning | 2 | 2011 | 16 | 0.400 |
Why?
|
| Mass Spectrometry | 3 | 2001 | 41 | 0.380 |
Why?
|
| Vasoconstrictor Agents | 2 | 2002 | 28 | 0.380 |
Why?
|
| Fructose | 2 | 2001 | 10 | 0.370 |
Why?
|
| Cerebrovascular Disorders | 1 | 2011 | 132 | 0.370 |
Why?
|
| Neuroprotective Agents | 3 | 2011 | 59 | 0.360 |
Why?
|
| Immunohistochemistry | 9 | 2009 | 391 | 0.360 |
Why?
|
| Tight Junctions | 1 | 2009 | 28 | 0.360 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 9 | 0.360 |
Why?
|
| Cytokines | 4 | 2006 | 347 | 0.360 |
Why?
|
| Interleukin-1 | 3 | 2004 | 78 | 0.360 |
Why?
|
| Serotonin Antagonists | 3 | 2000 | 19 | 0.350 |
Why?
|
| Anticonvulsants | 2 | 2001 | 109 | 0.350 |
Why?
|
| Uterus | 2 | 1998 | 15 | 0.330 |
Why?
|
| Female | 33 | 2011 | 16197 | 0.330 |
Why?
|
| Neurodegenerative Diseases | 2 | 2009 | 117 | 0.330 |
Why?
|
| Carotid Body | 2 | 1999 | 2 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2004 | 437 | 0.330 |
Why?
|
| Interleukin-6 | 2 | 1999 | 108 | 0.320 |
Why?
|
| Immune System | 1 | 2008 | 20 | 0.320 |
Why?
|
| Cell Survival | 7 | 2001 | 169 | 0.320 |
Why?
|
| Autoimmunity | 1 | 2008 | 19 | 0.320 |
Why?
|
| Serotonin | 4 | 2009 | 40 | 0.310 |
Why?
|
| Minocycline | 1 | 2007 | 8 | 0.300 |
Why?
|
| Behavior, Animal | 11 | 1996 | 105 | 0.290 |
Why?
|
| Fetus | 5 | 1999 | 56 | 0.290 |
Why?
|
| Hydroxydopamines | 1 | 2005 | 1 | 0.280 |
Why?
|
| Tissue Extracts | 3 | 2000 | 13 | 0.270 |
Why?
|
| Insecticides | 1 | 2004 | 3 | 0.260 |
Why?
|
| Rotenone | 1 | 2004 | 10 | 0.260 |
Why?
|
| Adrenal Medulla | 5 | 1991 | 31 | 0.250 |
Why?
|
| Endotoxins | 1 | 2004 | 24 | 0.240 |
Why?
|
| Tegmentum Mesencephali | 4 | 1991 | 7 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 2 | 2007 | 402 | 0.240 |
Why?
|
| Microglia | 5 | 2011 | 124 | 0.240 |
Why?
|
| Bacterial Toxins | 1 | 2003 | 21 | 0.240 |
Why?
|
| Apomorphine | 16 | 1990 | 37 | 0.230 |
Why?
|
| Receptors, Serotonin | 3 | 2000 | 21 | 0.220 |
Why?
|
| Glutathione | 3 | 2007 | 30 | 0.220 |
Why?
|
| Dopamine Agents | 4 | 2000 | 40 | 0.220 |
Why?
|
| Teratogens | 1 | 2002 | 1 | 0.220 |
Why?
|
| Placental Circulation | 1 | 2002 | 1 | 0.220 |
Why?
|
| Receptors, Dopamine | 5 | 1990 | 30 | 0.210 |
Why?
|
| Humans | 40 | 2011 | 29337 | 0.200 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 6 | 2005 | 30 | 0.200 |
Why?
|
| Dihydroxyphenylalanine | 2 | 2000 | 7 | 0.200 |
Why?
|
| Time Factors | 12 | 2013 | 1616 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2007 | 130 | 0.190 |
Why?
|
| Vitamin E | 2 | 1999 | 27 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 56 | 0.180 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 4 | 2008 | 7 | 0.180 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 1999 | 16 | 0.180 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 2011 | 5 | 0.180 |
Why?
|
| Benzothiazoles | 5 | 2002 | 20 | 0.180 |
Why?
|
| Cerebellum | 5 | 1999 | 57 | 0.180 |
Why?
|
| Parkinsonian Disorders | 4 | 2011 | 217 | 0.180 |
Why?
|
| Homovanillic Acid | 4 | 2009 | 9 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2002 | 145 | 0.170 |
Why?
|
| Analysis of Variance | 3 | 2011 | 321 | 0.170 |
Why?
|
| Cell Separation | 2 | 1997 | 42 | 0.170 |
Why?
|
| Embryo, Mammalian | 4 | 2001 | 31 | 0.170 |
Why?
|
| Disease Progression | 5 | 2013 | 787 | 0.170 |
Why?
|
| Antioxidants | 1 | 1999 | 56 | 0.170 |
Why?
|
| Permeability | 3 | 2013 | 134 | 0.170 |
Why?
|
| Pregnancy, Animal | 1 | 1998 | 3 | 0.170 |
Why?
|
| Culture Media, Conditioned | 4 | 1999 | 37 | 0.160 |
Why?
|
| alpha-Synuclein | 2 | 2013 | 138 | 0.160 |
Why?
|
| Self Administration | 2 | 2014 | 36 | 0.160 |
Why?
|
| Encephalitis | 3 | 2009 | 17 | 0.160 |
Why?
|
| Rats, Inbred Strains | 8 | 1991 | 33 | 0.160 |
Why?
|
| Membrane Transport Proteins | 1 | 1998 | 50 | 0.160 |
Why?
|
| Motor Activity | 6 | 2008 | 369 | 0.150 |
Why?
|
| Oxidative Stress | 3 | 2007 | 124 | 0.150 |
Why?
|
| Guinea Pigs | 14 | 1998 | 63 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 101 | 0.150 |
Why?
|
| Animals, Newborn | 4 | 2007 | 55 | 0.150 |
Why?
|
| Hallucinations | 1 | 1998 | 87 | 0.150 |
Why?
|
| Biomarkers | 4 | 2011 | 689 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 2 | 1994 | 18 | 0.150 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 2005 | 39 | 0.150 |
Why?
|
| Narcotics | 1 | 1996 | 34 | 0.140 |
Why?
|
| Apoptosis | 4 | 1999 | 251 | 0.140 |
Why?
|
| Brain Chemistry | 3 | 2006 | 47 | 0.140 |
Why?
|
| Lewy Bodies | 2 | 2008 | 195 | 0.130 |
Why?
|
| Movement Disorders | 1 | 1996 | 141 | 0.130 |
Why?
|
| Dyskinesia, Drug-Induced | 4 | 1985 | 54 | 0.130 |
Why?
|
| Antigens, CD | 3 | 2006 | 99 | 0.130 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 5 | 0.130 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2014 | 9 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 16 | 0.130 |
Why?
|
| Vasoconstriction | 1 | 2014 | 24 | 0.130 |
Why?
|
| Functional Laterality | 3 | 2005 | 91 | 0.130 |
Why?
|
| Drug Interactions | 7 | 2002 | 67 | 0.120 |
Why?
|
| Nitric Oxide | 1 | 2014 | 101 | 0.120 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1993 | 4 | 0.120 |
Why?
|
| Dopamine Antagonists | 3 | 1993 | 14 | 0.120 |
Why?
|
| Dopaminergic Neurons | 1 | 2014 | 44 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 432 | 0.120 |
Why?
|
| Mice | 5 | 2013 | 1607 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2005 | 36 | 0.110 |
Why?
|
| Neuronal Plasticity | 1 | 1992 | 43 | 0.110 |
Why?
|
| Autoantibodies | 2 | 1990 | 100 | 0.110 |
Why?
|
| Synapses | 1 | 1992 | 50 | 0.110 |
Why?
|
| Colon | 1 | 2013 | 148 | 0.110 |
Why?
|
| Neurotoxins | 2 | 2006 | 19 | 0.110 |
Why?
|
| Deoxyglucose | 2 | 1992 | 5 | 0.110 |
Why?
|
| 5-Hydroxytryptophan | 5 | 1986 | 12 | 0.100 |
Why?
|
| Drug Combinations | 5 | 1997 | 82 | 0.100 |
Why?
|
| Age Factors | 4 | 2008 | 843 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2011 | 13 | 0.100 |
Why?
|
| Injections, Intraventricular | 2 | 2004 | 13 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 16 | 0.100 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2011 | 44 | 0.100 |
Why?
|
| Antibodies | 1 | 1991 | 65 | 0.100 |
Why?
|
| Transplantation, Heterotopic | 2 | 1991 | 12 | 0.100 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 3 | 2006 | 17 | 0.100 |
Why?
|
| Benztropine | 2 | 1988 | 6 | 0.100 |
Why?
|
| Alzheimer Disease | 5 | 2009 | 1942 | 0.100 |
Why?
|
| Clozapine | 1 | 1990 | 10 | 0.100 |
Why?
|
| Cerebral Ventricles | 2 | 1996 | 23 | 0.090 |
Why?
|
| Lewy Body Disease | 1 | 2011 | 98 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 1996 | 129 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1989 | 49 | 0.090 |
Why?
|
| Ergolines | 3 | 1999 | 14 | 0.090 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 251 | 0.090 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 1989 | 2 | 0.090 |
Why?
|
| Hallucinogens | 1 | 1989 | 3 | 0.090 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 30 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2008 | 13 | 0.090 |
Why?
|
| Caspases | 2 | 1999 | 32 | 0.090 |
Why?
|
| Thioridazine | 5 | 1990 | 9 | 0.090 |
Why?
|
| Leukemia Inhibitory Factor | 2 | 1999 | 3 | 0.090 |
Why?
|
| Lymphokines | 2 | 1999 | 9 | 0.080 |
Why?
|
| Parasympatholytics | 2 | 1986 | 14 | 0.080 |
Why?
|
| Growth Inhibitors | 2 | 1999 | 14 | 0.080 |
Why?
|
| Methiothepin | 2 | 1999 | 5 | 0.080 |
Why?
|
| Environmental Pollutants | 1 | 2008 | 3 | 0.080 |
Why?
|
| Oxadiazoles | 2 | 1999 | 12 | 0.080 |
Why?
|
| Amniotic Fluid | 2 | 1998 | 6 | 0.080 |
Why?
|
| Aged | 10 | 2011 | 9448 | 0.080 |
Why?
|
| Body Weight | 1 | 2008 | 133 | 0.080 |
Why?
|
| Multiple Sclerosis | 2 | 2008 | 87 | 0.080 |
Why?
|
| Environment | 1 | 2008 | 46 | 0.080 |
Why?
|
| Tropanes | 1 | 1988 | 4 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 1999 | 146 | 0.080 |
Why?
|
| Cell Division | 2 | 2001 | 113 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 87 | 0.080 |
Why?
|
| Piperazines | 2 | 1999 | 90 | 0.080 |
Why?
|
| Deoxy Sugars | 1 | 1987 | 1 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 81 | 0.080 |
Why?
|
| Diencephalon | 1 | 1987 | 1 | 0.080 |
Why?
|
| Kainic Acid | 1 | 1987 | 2 | 0.080 |
Why?
|
| Albumins | 2 | 2005 | 33 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2001 | 788 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 1987 | 52 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 55 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 54 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 211 | 0.070 |
Why?
|
| Enzymes | 1 | 2006 | 5 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 2006 | 16 | 0.070 |
Why?
|
| Herbicides | 1 | 2006 | 3 | 0.070 |
Why?
|
| Pesticides | 1 | 2006 | 3 | 0.070 |
Why?
|
| Hazardous Substances | 1 | 2006 | 2 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2007 | 303 | 0.070 |
Why?
|
| Horseradish Peroxidase | 1 | 2005 | 5 | 0.070 |
Why?
|
| Integrin beta3 | 1 | 2005 | 6 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 1998 | 22 | 0.070 |
Why?
|
| Synucleins | 1 | 2004 | 7 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2004 | 63 | 0.060 |
Why?
|
| Risk Factors | 2 | 2014 | 2443 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2003 | 30 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 441 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2011 | 4851 | 0.060 |
Why?
|
| Rabbits | 2 | 1994 | 280 | 0.060 |
Why?
|
| Culture Media | 2 | 1994 | 38 | 0.050 |
Why?
|
| Axons | 2 | 1992 | 38 | 0.050 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 1999 | 2 | 0.050 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 2 | 1999 | 3 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 1999 | 10 | 0.050 |
Why?
|
| Oligopeptides | 2 | 1999 | 30 | 0.050 |
Why?
|
| Nucleus Accumbens | 2 | 2014 | 25 | 0.050 |
Why?
|
| Heart Arrest | 2 | 2001 | 58 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2001 | 7 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2001 | 8 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2001 | 8 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 33 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2001 | 78 | 0.050 |
Why?
|
| Estrogens | 1 | 2001 | 33 | 0.050 |
Why?
|
| Growth Substances | 2 | 1991 | 41 | 0.050 |
Why?
|
| Prednisone | 1 | 2001 | 67 | 0.050 |
Why?
|
| Drug Stability | 2 | 1997 | 9 | 0.050 |
Why?
|
| Sympatholytics | 2 | 1999 | 14 | 0.050 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2011 | 21 | 0.050 |
Why?
|
| Brain Mapping | 3 | 2009 | 195 | 0.050 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 2000 | 5 | 0.050 |
Why?
|
| Temperature | 2 | 1997 | 76 | 0.050 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 48 | 0.050 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2000 | 4 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 8 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2000 | 89 | 0.050 |
Why?
|
| Mitochondria | 2 | 1999 | 78 | 0.050 |
Why?
|
| GAP-43 Protein | 1 | 1999 | 2 | 0.040 |
Why?
|
| Middle Aged | 6 | 1996 | 9823 | 0.040 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1999 | 5 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1999 | 31 | 0.040 |
Why?
|
| Chloroform | 1 | 1999 | 1 | 0.040 |
Why?
|
| Fluorenes | 1 | 1999 | 3 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 553 | 0.040 |
Why?
|
| Catecholamines | 1 | 1999 | 13 | 0.040 |
Why?
|
| Quality Control | 1 | 1999 | 43 | 0.040 |
Why?
|
| Acoustic Stimulation | 1 | 1999 | 47 | 0.040 |
Why?
|
| Schizophrenia | 2 | 1996 | 77 | 0.040 |
Why?
|
| Fetal Monitoring | 1 | 1998 | 1 | 0.040 |
Why?
|
| Molecular Weight | 1 | 1998 | 45 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 1998 | 26 | 0.040 |
Why?
|
| Dopa Decarboxylase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Gestational Age | 1 | 1998 | 73 | 0.040 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 1998 | 12 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1998 | 4 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 29 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 76 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 1998 | 26 | 0.040 |
Why?
|
| Solutions | 1 | 1997 | 19 | 0.040 |
Why?
|
| Cell Membrane | 1 | 1998 | 105 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 223 | 0.040 |
Why?
|
| Tissue Preservation | 1 | 1997 | 6 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 1998 | 97 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 1996 | 503 | 0.040 |
Why?
|
| Erythropoietin | 1 | 1998 | 55 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 1997 | 44 | 0.040 |
Why?
|
| Reference Values | 2 | 1995 | 227 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 1997 | 10 | 0.040 |
Why?
|
| Lithium | 2 | 1990 | 23 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 148 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1996 | 12 | 0.040 |
Why?
|
| Respiration | 1 | 1996 | 35 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 1996 | 50 | 0.040 |
Why?
|
| Astrocytes | 1 | 1998 | 122 | 0.040 |
Why?
|
| Caudate Nucleus | 2 | 1993 | 18 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 1996 | 123 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 1995 | 29 | 0.030 |
Why?
|
| Antipsychotic Agents | 3 | 1985 | 82 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2014 | 12 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1994 | 12 | 0.030 |
Why?
|
| Reward | 1 | 2014 | 34 | 0.030 |
Why?
|
| Chlorpromazine | 3 | 1985 | 11 | 0.030 |
Why?
|
| Vagus Nerve | 1 | 2013 | 14 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 12 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2014 | 83 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 12 | 0.030 |
Why?
|
| Putamen | 1 | 1993 | 23 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2005 | 65 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 254 | 0.030 |
Why?
|
| Dendrites | 1 | 1992 | 15 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 1992 | 46 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 1991 | 195 | 0.030 |
Why?
|
| Postmortem Changes | 1 | 2011 | 34 | 0.030 |
Why?
|
| Chromogranins | 1 | 1991 | 4 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1982 | 100 | 0.030 |
Why?
|
| Rotation | 1 | 1991 | 142 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1991 | 13 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1991 | 298 | 0.020 |
Why?
|
| Fluphenazine | 3 | 1986 | 8 | 0.020 |
Why?
|
| Spiperone | 1 | 1990 | 3 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1990 | 29 | 0.020 |
Why?
|
| Amantadine | 1 | 1990 | 15 | 0.020 |
Why?
|
| Pheochromocytoma | 1 | 1990 | 6 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 11 | 0.020 |
Why?
|
| Cholinergic Fibers | 1 | 1990 | 6 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1990 | 145 | 0.020 |
Why?
|
| Denervation | 1 | 1989 | 21 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 14 | 0.020 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2009 | 1 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 37 | 0.020 |
Why?
|
| Raphe Nuclei | 1 | 2009 | 8 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2009 | 6 | 0.020 |
Why?
|
| Mescaline | 1 | 1989 | 1 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1989 | 12 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1113 | 0.020 |
Why?
|
| Caspase 3 | 2 | 1999 | 30 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2009 | 81 | 0.020 |
Why?
|
| Amygdala | 1 | 2009 | 50 | 0.020 |
Why?
|
| Exercise | 1 | 1993 | 468 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 288 | 0.020 |
Why?
|
| Adult | 3 | 1996 | 8601 | 0.020 |
Why?
|
| Research | 1 | 2008 | 54 | 0.020 |
Why?
|
| Sex Factors | 2 | 2002 | 496 | 0.020 |
Why?
|
| Autoradiography | 1 | 1987 | 11 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2009 | 294 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2007 | 9 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 43 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 53 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 109 | 0.020 |
Why?
|
| Hippocampus | 1 | 2009 | 274 | 0.020 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2006 | 4 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2006 | 3 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 6 | 0.020 |
Why?
|
| Homeostasis | 1 | 2007 | 82 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 83 | 0.020 |
Why?
|
| Trihexyphenidyl | 1 | 1986 | 5 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 73 | 0.020 |
Why?
|
| Tremorine | 1 | 1986 | 2 | 0.020 |
Why?
|
| Lisuride | 1 | 1986 | 4 | 0.020 |
Why?
|
| Bromocriptine | 1 | 1986 | 15 | 0.020 |
Why?
|
| Naloxone | 1 | 1986 | 12 | 0.020 |
Why?
|
| Clonazepam | 1 | 1986 | 29 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 112 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 213 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 125 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2005 | 10 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 25 | 0.020 |
Why?
|
| Protein Folding | 1 | 2005 | 18 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2005 | 44 | 0.020 |
Why?
|
| Morphine | 1 | 1986 | 79 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 85 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2006 | 132 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2005 | 170 | 0.020 |
Why?
|
| Proteins | 1 | 2005 | 72 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 248 | 0.020 |
Why?
|
| Genotype | 1 | 2005 | 405 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1983 | 21 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 383 | 0.010 |
Why?
|
| Haplorhini | 1 | 1983 | 12 | 0.010 |
Why?
|
| Amphetamine | 1 | 1983 | 13 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 26 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 66 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 61 | 0.010 |
Why?
|
| Drug Implants | 1 | 2001 | 11 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2001 | 26 | 0.010 |
Why?
|
| Lentivirus | 1 | 2000 | 11 | 0.010 |
Why?
|
| Estradiol | 1 | 2001 | 58 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2000 | 60 | 0.010 |
Why?
|
| S-Adenosylmethionine | 1 | 2000 | 6 | 0.010 |
Why?
|
| Tyrosine | 1 | 2000 | 23 | 0.010 |
Why?
|
| Benzophenones | 1 | 2000 | 27 | 0.010 |
Why?
|
| Gene Expression | 1 | 2000 | 226 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 7 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 1999 | 6 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2000 | 216 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 1999 | 24 | 0.010 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1996 | 3 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 26 | 0.010 |
Why?
|
| Drug Storage | 1 | 1996 | 2 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1996 | 32 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 1995 | 25 | 0.010 |
Why?
|
| Light | 1 | 1996 | 76 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1995 | 495 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1993 | 9 | 0.010 |
Why?
|
| Models, Biological | 2 | 1986 | 343 | 0.010 |
Why?
|
| Chromogranin A | 1 | 1991 | 13 | 0.010 |
Why?
|
| Circadian Rhythm | 2 | 1982 | 280 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1988 | 38 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 324 | 0.000 |
Why?
|
| Receptors, Muscarinic | 1 | 1986 | 7 | 0.000 |
Why?
|
| Bismuth | 1 | 1986 | 2 | 0.000 |
Why?
|
| Gasoline | 1 | 1986 | 2 | 0.000 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1986 | 2 | 0.000 |
Why?
|
| Methysergide | 1 | 1986 | 7 | 0.000 |
Why?
|
| Imipramine | 1 | 1986 | 13 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1991 | 1830 | 0.000 |
Why?
|
| Anesthetics | 1 | 1986 | 25 | 0.000 |
Why?
|
| Antidepressive Agents | 1 | 1986 | 100 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1986 | 140 | 0.000 |
Why?
|
| Sleep | 1 | 1986 | 313 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1982 | 43 | 0.000 |
Why?
|
| Membranes | 1 | 1980 | 9 | 0.000 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1979 | 4 | 0.000 |
Why?
|